INSP - Inspire Medical Systems, Inc.
| Previous Close | 56.75 |
| Open | 57.05 |
| Bid | 57.20 x 1200 |
| Ask | 0.00 x 800 |
| Day's Range | 56.88 - 58.95 |
| 52 Week Range | 22.50 - 59.89 |
| Volume | 181,675 |
| Avg. Volume | 310,431 |
| Market Cap | 1.329B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.26 |
| Earnings Date | Feb 26, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.75 |
- GlobeNewswire•9 days ago
Inspire Medical Systems, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Inspire Medical Systems, Inc. (INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the 8th Annual SVB Leerink Global Healthcare Conference on February 28, 2019 at the Lotte New York Palace in New York. Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
- Motley Fool•15 days ago
4 Disruptive Healthcare Stocks You've Never Heard Of
Do these under-the-radar stocks deserve a spot in your growth stock portfolio?
- GlobeNewswire•18 days ago
Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2018 Financial Results on February 26
MINNEAPOLIS, Feb. 05, 2019 -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of.
- GlobeNewswire•18 days ago
Inspire Medical Systems, Inc. Announces Additional Positive Coverage Policies Issued by Five Blue Cross Blue Shield Healthcare Plans
MINNEAPOLIS, Feb. 05, 2019 -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of.
- Zacks•22 days ago
What's in the Cards for Match Group (MTCH) in Q4 Earnings?
Match Group (MTCH) is benefiting from increasing subscriber addition in the form of membership subscriptions. Tinder remains the key catalyst.
- GlobeNewswire•23 days ago
Inspire Medical Systems, Inc. Announces a Positive Coverage Policy Issued by Blue Cross Blue Shield of North Carolina
Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that Blue Cross Blue Shield of North Carolina (“BCBSNC”) has issued a positive coverage policy of Inspire therapy. This is the third coverage policy issued by a Blue Cross Blue Shield Association (“BCBSA”) healthcare plan following BCBSA Evidence Street’s January 7, 2019 report, which stated that there is sufficient evidence to determine that Inspire therapy results in a meaningful improvement in net health outcomes for patients meeting specified criteria. BCBSNC, an independent licensee of BCBSA, is the state of North Carolina’s largest insurer and covers approximately 3.9 million members.
- GlobeNewswire•25 days ago
Inspire Medical Systems, Inc. Announces FDA Approval of New Sensing Lead
“We are pleased to receive FDA approval of the new sensing lead for Inspire therapy,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
- GlobeNewswire•last month
Inspire Medical Systems, Inc. Announces a Positive Coverage Policy Issued by Horizon Blue Cross Blue Shield of New Jersey
Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that Horizon Blue Cross Blue Shield of New Jersey (“Horizon BCBSNJ”) has issued a positive coverage policy of Inspire therapy. This is the second coverage policy issued by a Blue Cross Blue Shield Association (“BCBSA”) healthcare plan following BCBSA Evidence Street’s January 7, 2019 report, which stated that there is sufficient evidence to determine that Inspire therapy results in a meaningful improvement in net health outcomes for patients meeting specified criteria.
- GlobeNewswire•last month
Inspire Medical Systems, Inc. Announces First BCBS Coverage Policy following Evidence Street’s Positive Therapy Indication Summary
Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that Blue Cross of Idaho has issued a positive coverage policy of Inspire therapy. This is the first coverage policy issued following BCBS Evidence Street’s January 7, 2019 report, which stated there is sufficient evidence to determine that Inspire therapy results in a meaningful improvement in net health outcomes for patients meeting specified criteria. Blue Cross of Idaho, the state of Idaho’s leading health insurer, is a not-for-profit mutual insurance company covering approximately 500,000 members. Blue Cross of Idaho is an independent licensee of the Blue Cross and Blue Shield Association (BCBSA).
- GlobeNewswire•2 months ago
Inspire Medical Systems, Inc. Announces Issuance of Positive Assessment for Inspire Therapy by Blue Cross Blue Shield Association’s Evidence Street
Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that the Blue Cross Blue Shield Association's (“BCBSA”) Evidence Street issued a positive assessment of Inspire therapy to its members. BCBSA is a national federation of 36 Blue Cross and Blue Shield (“BCBS”) companies that, when combined, is one of the leading health associations in the U.S.
- GlobeNewswire•2 months ago
Inspire Medical Systems, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS, Dec. 19, 2018 -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative.
- GlobeNewswire•2 months ago
Inspire Medical Systems, Inc. Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that the underwriters of its previously announced offering of 2,500,000 shares of its common stock, consisting of 1,500,000 shares offered by Inspire and 1,000,000 shares offered by certain stockholders of Inspire (the “Selling Stockholders”), have exercised in full their option to purchase an additional 375,000 shares of its common stock at a public offering price of $40.00 per share, less underwriting discounts and commissions. The exercise of the option brings the total shares of common stock sold by Inspire in the offering to 1,875,000 shares.
- Simply Wall St.•2 months ago
Are Inspire Medical Systems, Inc.’s (NYSE:INSP) Interest Costs Too High?
While small-cap stocks, such as Inspire Medical Systems, Inc. (NYSE:INSP) with its market cap of US$947m, are popular for their explosive growth, investors should also be aware of their balance Read More...
- GlobeNewswire•3 months ago
Inspire Medical Systems, Inc. Announces Pricing of Offering of Common Stock
Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today the pricing of the previously announced offering of 2,500,000 shares of its common stock, consisting of 1,500,000 shares offered by Inspire and 1,000,000 shares offered by certain stockholders of Inspire (the “Selling Stockholders”), at a public offering price of $40.00 per share, before underwriting discounts and commissions. In addition, Inspire has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
- GlobeNewswire•3 months ago
Inspire Medical Systems, Inc. Announces Proposed Offering of Common Stock
Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today the commencement of a proposed public offering of 2,500,000 shares of its common stock, consisting of 1,500,000 shares offered by Inspire and 1,000,000 shares offered by certain stockholders of Inspire (the “Selling Stockholders”). Inspire also expects to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of common stock. Inspire will not receive any proceeds from the sale of common stock offered by the Selling Stockholders.
- GlobeNewswire•3 months ago
Inspire Medical Systems, Inc. Announces Publication of Data From ADHERE Registry
Inspire Medical Systems, Inc. (INSP) ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced today the publication of data from the first 508 Inspire therapy patients included in the 2,500-patient ADHERE registry. The data demonstrated that Inspire therapy is an effective treatment option with high patient satisfaction and low adverse events. These results represent the largest international data set for Inspire therapy generated to date. The publication, entitled “Post-Approval Upper Airway Stimulation Predictors of Treatment Efficacy in the Adhere Registry,” is available online (http://erj.ersjournals.com/content/early/2018/10/25/13993003.01405-2018) in the European Respiratory Journal, the flagship journal of the European Respiratory Society. The lead authors of the publication are Dr. Clemens Heiser of the Technische Universität in Munich, and Dr. Maurits Boon of Thomas Jefferson University Hospital.
